Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 42.9% during trading on Tuesday . The stock traded as high as C$0.11 and last traded at C$0.10. 370,639 shares changed hands during mid-day trading, an increase of 290% from the average session volume of 95,035 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The firm has a market capitalization of C$9.15 million, a price-to-earnings ratio of -5.25 and a beta of 0.20. The business’s 50 day moving average price is C$0.08 and its 200-day moving average price is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 3 Small Caps With Big Return Potential
- 3 Stocks Helping to Bring AI to Healthcare
- When to Sell a Stock for Profit or Loss
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- 3 Monster Growth Stocks to Buy Now
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
